Screener / SEC EDGAR /CIK 0001723128 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Amneal Pharmaceuticals, Inc. AMRX

Compare with peers Embed
Earnings releases

Latest results release: Nov 3, 2026

8-K item 2.02, exhibit 99

What AMRX's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 3, 2026, AMRX reported −$0.06 per share under GAAP and $0.26 on its own adjusted basis.

GAAP EPS $-0.40, release Mar 1, 2024: Diluted loss per share in the fourth quarter of 2023 was $0.40, an increase of $0.37 from a loss of $0 Adjusted EPS $0.14, release Mar 1, 2024: Adjusted diluted EPS (1) in the fourth quarter of 2023 was $0.14, a decrease of 39% from $0.23 in the fourth quarter of 2022. 2024-03 GAAP EPS $-0.30, release May 3, 2024: GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million Adjusted EPS $0.14, release May 3, 2024: Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in p 2024-05 GAAP EPS $0.02, release Aug 9, 2024: Diluted income per share in the second quarter of 2024 was $0.02 compared to $0.08 for the second quarter of 2023, primarily due to lower net income. Adjusted EPS $0.16, release Aug 9, 2024: Adjusted diluted earnings per share in the second quarter of 2024 was $0.16 compared to $0.19 for the second quarter of 2023 due to the aforementioned factor. +700% 2024-08 GAAP EPS $-0.00, release Nov 8, 2024: Diluted loss per share in the third quarter of 2024 was $0.00 compared to diluted income per share of $0.06 for the third quarter of 2023, as higher interest expense reduced net income. Adjusted EPS $0.16, release Nov 8, 2024: Adjusted diluted earnings per share in the third quarter of 2024 was $0.16 compared to $0.19 for the third quarter of 2023 due to the aforementioned factor. 2024-11 GAAP EPS $-0.10, release Feb 28, 2025: Diluted loss per share in the fourth quarter of 2024 was $0.10 compared to a loss of $0.40 for the fourth quarter of 2023, due to the aforementioned factors. Adjusted EPS $0.12, release Feb 28, 2025: Adjusted diluted EPS (1) in the fourth quarter of 2024 was $0.12 compared to $0.14 in the fourth quarter of 2023. 2025-02 GAAP EPS $0.07, release Aug 5, 2025: Diluted income per share in the second quarter of 2025 was $0.07 compared to diluted income per share of $0.02 for the second quarter of 2024, due to higher operating income and favorable foreign exchange. Adjusted EPS $0.25, release Aug 5, 2025: Adjusted diluted earnings per share in the second quarter of 2025 was $0.25, an increase of 56%, compared to $0.16 for the second quarter of 2024. +257% 2025-08 GAAP EPS $0.01, release Oct 30, 2025: Diluted income per share in the third quarter of 2025 was $0.01 compared to diluted loss per share of $0.00 for the third quarter of 2024, due to the aforementioned factors. Adjusted EPS $0.17, release Oct 30, 2025: Adjusted diluted earnings per share in the third quarter of 2025 was $0.17, an increase of 6% compared to $0.16 for the third quarter of 2024. +1600% 2025-10 GAAP EPS $0.11, release Feb 27, 2026: Diluted income per share in the fourth quarter of 2025 was $0.11 compared to a loss of $0.10 for the fourth quarter of 2024 due to the aforementioned factors as well as lower interest expense. Adjusted EPS $0.21, release Feb 27, 2026: Adjusted diluted EPS in the fourth quarter of 2025 was $0.21 compared to $0.12 in the fourth quarter of 2024. +91% 2026-02 GAAP EPS $0.19, release May 7, 2026: GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million Adjusted EPS $0.27, release May 7, 2026: Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results +42% 2026-05 GAAP EPS $0.18, release Jul 30, 2026: GAAP Net Income of $58 million; Diluted Income per Share of $0.18 Adjusted EPS $0.30, release Jul 30, 2026: Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 +67% 2026-07 GAAP EPS $-0.06, release Nov 3, 2026: GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) Adjusted EPS $0.26, release Nov 3, 2026: Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) release
Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 release

What the company says its adjusted numbers leave out:

Adjusted EBITDA reflects net income (loss) adjusted to exclude (i) interest expense, net, (ii) provision for income taxes, (iii) depreciation and amortization, (iv) stock- based compensation expense, (v) acquisition, site closure, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing, (viii) charges (credit) related to legal matters, net, (ix) asset impairment charges, (x) foreign exchange loss (gain), (xi) increase in tax receivable agreement liability, and (xii) other. release Feb 27, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 3, 2026 · EX-99.1

AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Open on SEC

– Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) –

– Updating 2026 Full Year Guidance – BRIDGEWATER, NJ, November 3, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2026.

“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT ® , and BREKIYA ® autoinjector. The Kashiv integration is proceeding well, and we are excited about the long-term growth potential in biosimilars. With the breadth and depth of opportunities across our portfolio, we remain highly confident in Amneal’s robust growth outlook,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.

Net revenue in the third quarter of 2026 was $863 million, an increase of 10% compared to $785 million in the third quarter of 2025. Affordable Medicines net revenue increased 19%, driven by biosimilars, women’s health patches, and new launches. Specialty net revenue increased 20%, driven by key branded products, including CREXONT ® , BREKIYA ® autoinjector, and UNITHROID ® . AvKARE net revenue decreased 17%, as expected, due to a non-recurring cardiovascular product launch in the prior year.

Net loss attributable to Amneal Pharmaceuticals, Inc. was $22 million in the third quarter of 2026 compared to net income of $2 million in the third quarter of 2025 as higher revenue and gross profit were more than offset by non- recurring acquisition and integration costs, and higher tax provision.

Adjusted EBITDA in the third quarter of 2026 was $207 million, an increase of 30% compared to the third quarter of 2025, reflecting higher revenue, higher gross profit, and lower operating expenses.

Diluted loss per share in the third quarter of 2026 was $(0.06) compared to diluted income per share of $0.01 for the third quarter of 2025, due to the aforementioned factors and higher share count as a result of the Kashiv acquisition. Adjusted diluted earnings per share in the third quarter of 2026 was $0.26, an increase of 53% compared to $0.17 for the third quarter of 2025.

The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information. 1

We are increasing full year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS. The Company is also updating operating cash flow guidance, reflecting working capital, including higher inventory levels in key growth areas.

Updated Guidance Prior Guidance Net revenue $3.15 billion - $3.25 $3.10 billion - $3.20 billion billion Adjusted EBITDA(1) $800 million - $815 $750 million - $780 million million Adjusted diluted $1.04 - $1.08 $0.96 - $1.06 EPS(2) Operating cash flow(3) $325 million - $375 $350 million - $400 million million Operating cash flow, $350 million - $400 $375 million - $425 excluding discrete million million items(4) Capital ~$150 million ~$150 million expenditures(5)

(1) Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.

(2) Accounts for non-controlling interest in AvKARE. Assumes approximately 340 million weighted-average diluted shares outstanding for the year ending December 31, 2026.

(3) Represents cash provided by operating activities. (4) Excludes discrete items such as opioid settlement costs of approximately $36 million and Kashiv acquisition and integration costs of approximately $40 million.

(5) Reflects estimated capital expenditures and deposits for future acquisition of property, plant, and equipment. Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, November 3, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 304152835. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://help.events.q4inc.com/eahc/international-dial-in-numbers.

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding product launches; statements regarding our potential growth and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other 2 events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: risks related to integrating our acquisition (the “Kashiv Acquisition”) of Kashiv BioSciences, LLC (“Kashiv”) and realizing the anticipated benefits of the acquisition; our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross margin, adjusted operating income, net debt, gross leverage, and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP.

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non- GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results and facilitate an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working 3 capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as an alternative to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 157,399 $ 282,029 Restricted cash 14,174 28,842 Trade accounts receivable, 1,016,844 895,143 net Inventories 707,956 606,302 Prepaid expenses and other current 196,769 98,395 assets Related party receivables 1,876 470 Total current assets 2,095,018 1,911,181 Property, plant and 572,634 442,950 equipment, net Goodwill and intangible 2,323,728 1,158,968 assets, net Operating lease 69,760 38,832 right-of-use assets Operating lease right-of-use assets - 20,019 15,216 related party Financing lease 63,255 53,328 right-of-use assets Other assets 122,807 57,805 Total assets $ 5,267,221 $ 3,678,280 Liabilities and Stockholders’ Equity (Deficiency) Current liabilities: Accounts payable and $ 788,831 $ 761,316 accrued expenses Current portion of liabilities for legal 27,534 43,256 matters Revolving credit facility 180,000 — Current portion of 23,933 6,761 long-term debt, net Current portion of operating lease 14,417 8,668 liabilities Current portion of operating lease 3,398 2,705 liabilities - related party Current portion of financing lease 3,811 3,442 liabilities Related party payables - 18,913 55,485 short term Contingent consideration - related party 59,000 — - short term Total current liabilities 1,119,837 881,633 Long-term debt, net 2,915,501 2,565,115 Operating lease liabilities 59,612 33,233 Operating lease liabilities - related 16,635 14,195 party Financing lease liabilities 65,588 54,927 Related party payables - 15,878 19,132 long term Liabilities for legal matters - long 71,663 71,819 term Contingent consideration - related party 324,000 — - long term Other long-term liabilities 37,797 32,263 Total long-term liabilities 3,506,674 2,790,684 Redeemable non-controlling 109,453 77,292 interests Total stockholders’ equity 531,257 -71,329 (deficiency) Total liabilities and stockholders’ $ 5,267,221 $ 3,678,280 equity (deficiency)

Cash flows from Nine Months Ended operating September 30, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 159,920 $ 78,360 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 144,250 174,345 amortization Unrealized foreign 13,571 -8,606 currency loss (gain) Amortization of debt issuance costs and 12,141 18,716 discount Reclassification of 8,730 -1,713 cash flow hedge Loss on refinancing 9,270 31,365 Intangible asset 975 22,784 impairment charges Research and development 13,832 — equipment impairment charges Non-cash property 5,035 — losses Change in fair value of contingent -6,000 — consideration Stock-based 29,723 23,751 compensation Inventory provision 64,981 59,326 Other operating charges and credits, 4,689 3,575 net Changes in assets and liabilities: Trade accounts -122,423 -110,228 receivable, net Inventories -158,346 -66,846 Prepaid expenses, other current assets -113,073 -20,173 and other assets Related party 203 -830 receivables Accounts payable, accrued expenses and 17,590 2,744 other liabilities Related party -34,756 3,107 payables Net cash provided by operating 50,312 209,677 activities Cash flows from investing activities: Acquisition of Kashiv, net of cash and -421,047 — restricted cash acquired Purchases of property, plant and -70,659 -48,290 equipment Acquisition of -96,603 -12,514 intangible assets Deposits for future acquisition of -28,376 -7,384 property, plant and equipment Proceeds from sale of property, plant — 1,379 and equipment Net cash used in -616,685 -66,809 investing activities Cash flows from financing activities: Payments of principal on debt, revolving -293,172 -2,805,384 credit facilities, financing leases and other Proceeds from 529,853 2,694,750 issuance of debt Payments of deferred financing and -7,549 -74,973 refinancing costs Borrowings on revolving credit 280,000 218,000 facilities Proceeds from exercise of stock 516 1,407 options Employee payroll tax withholding on restricted stock -44,696 -21,957 unit and performance stock unit vesting Tax and other distributions to -29,571 -38,825 non-controlling interests Proceeds from 510 5,572 alliance party Acquisition of non-controlling -400 — interest Net cash provided by (used in) financing 435,491 -21,410 activities Effect of foreign exchange rate on -1,804 -1,471 cash Net decrease in cash, cash -132,686 119,987 equivalents, and restricted cash Cash, cash equivalents, and restricted 312,939 118,420 cash - beginning of period Cash, cash equivalents, and $ 180,253 $ 238,407 restricted cash - end of period Cash and cash equivalents - end of $ 157,399 $ 201,249 period Restricted cash - 14,174 34,727 end of period Long-term restricted cash included in 8,680 2,431 other assets - end of period Cash, cash equivalents, and $ 180,253 $ 238,407 restricted cash - end of period

Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share

(1) Acquisition, site closure, and idle facility expenses for the three and nine months ended September 30, 2026 primarily included acquisition costs associated with the acquisition of Kashiv and rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three and nine months ended September 30, 2025 and year ended December 31, 2025 primarily included costs related to a planned facility closure and rent for vacated properties.

(2) Loss on refinancing for the three and nine months ended September 30, 2026 was primarily comprised of debt issuance costs and the write-off of unamortized debt issuance costs. In February 2026, the Company entered into a repricing amendment for the Company’s Term Loan Due 2032 (the “February 2026 Repricing Amendment”), which reduced the applicable interest rate margins on such term loan. In August 2026, the Company entered into another repricing amendment for the Company’s Term Loan Due 2032 (the “August 2026 Repricing Amendment”), which further reduced the applicable interest rate margins on such term loan. Also in August 2026, the Company borrowed an additional $350.0 million under Amendment No. 4 to the Company’s Term Loan Credit Agreement (the “Incremental Term Loans”) to fund a portion of the cash consideration for the Kashiv Acquisition. The loss for the three months ended September 30, 2026 primarily reflects costs associated with the August 2026 Repricing Amendment and the Incremental Term Loans, while the loss for the nine months ended September 30, 2026 primarily reflects costs associated with the February 2026 Repricing Amendment, the August 2026 Repricing Amendment and the Incremental Term Loans. For 2025, loss on refinancing was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2028 that was modified as part of the Company’s debt refinancing on August 1, 2025. Refer to Not e 14. Debt in the Company’s 2025 Annual Report on Form 10-K for information about the Company’s debt as of December 31, 2025.

(3) For the three months ended September 30, 2026, charges related to legal matters, net were $7.5 million, primarily consisting of a charge related to government investigations of $8.0 million, partially offset by immaterial net credits related to several matters. For the nine months ended September 30, 2026, charges related to legal matters, net were $16.3 million , primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date, (ii) net charges associated with antitrust class action litigation of $7.5 million, (iii) a charge related to government investigations of $8.0 million, and (iv) immaterial net charges related to several matters. For the three and nine months ended September 30, 2026, charges related to legal matters, including interest, net also included interest expense associated with the Nationwide Opioids Settlement Agreement. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

(4) For the three and nine months ended September 30, 2026, impairment charges related to certain equipment used in research and development activities as a result of a change in the expected future utilization of the assets as well as an immaterial intangible asset impairment. For 2025, asset impairment charges primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application.

(5) During the three and nine months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.

(7) For the year ended December 31, 2025, the caption “other” primarily reflects a non-recurring, non-operating, non-cash gain.

(8) Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for additional information about the Company’s debt. On August 10, 2026, the Company borrowed an additional $350.0 million under its Term Loan Due 2032, with substantially the same terms as the existing term loans, primarily to finance a portion of the cash consideration for the Kashiv Acquisition. Additionally, in connection with the Kashiv Acquisition, the Company assumed the Kashiv Rupee Term Loan Facility. The Company repaid the facility in full and terminated it on October 1, 2026.

(9) Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents.

(10) Gross leverage was calculated by dividing gross debt as of September 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended September 30, 2026 and year ended December 31, 2025, respectively.

(11) Net leverage was calculated by dividing net debt as of September 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended September 30, 2026 and year ended December 31, 2025, respectively.

(12) The non-GAAP effective tax rates for the three and nine months ended September 30, 2026 were 24.0% and 24.5%, respectively. The non-GAAP effective tax rates for the three and nine months ended September 30, 2025 were 23.7% and 24.7%, respectively.

(13) Weighted-average diluted shares outstanding for the three and nine months ended September 30, 2026 and 2025 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities). 11

(1) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.1 million and $0.9 million), amortization expense ($36.0 million and $36.9 million), amortization of acquired inventory step-up ($0.9 million and none), and asset impairment charges ($1.0 million and $22.8 million).

(2) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($8.6 million and $6.5 million), amortization expense ($2.6 million and $2.7 million), site closure costs ($0.4 million and $0.6 million), and other ($1.4 million and $1.3 million).

(3) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.9 million and $0.7 million), asset impairment charges ($13.8 million and none), and site closure costs (none and $1.8 million).

(4) Acquisition and integration costs for the three months ended September 30, 2026 were primarily related to professional services fees (e.g., investment banking, legal, due diligence, financial advisory, accounting, and consulting) associated with the acquisition and integration of Kashiv.

(5) During the three months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.

(7) Adjustments to charges (credit) related to legal matters, net were $7.5 million for the three months ended September 30, 2026, primarily consisting of a charge related to government investigations of $8.0 million, partially offset by immaterial net credits related to several matters. 12

(1) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($3.1 million and $2.8 million), amortization expense ($95.6 million and $122.5 million), amortization of acquired inventory step-up ($0.9 million and none), and asset impairment charges ($1.0 million and $22.9 million).

(2) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($24.2 million and $18.4 million), amortization expense ($7.9 million and $8.1 million), site closure costs ($1.4 million and $1.6 million), and other ($4.6 million and $4.0 million).

(3) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.5 million and $2.4 million), asset impairment charges ($13.8 million and none), and site closure costs (none and $3.2 million).

(4) Acquisition and integration costs for the nine months ended September 30, 2026 were primarily related to professional services fees (e.g., investment banking, legal, due diligence, financial advisory, accounting, and consulting) associated with the acquisition and integration of Kashiv.

(5) During the nine months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.

(7) Adjustments to charges (credit) related to legal matters, net were $16.3 million for the nine months ended September 30, 2026, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date, (ii) net charges associated with antitrust class action litigation of $7.5 million, (iii) a charge related to government investigations of $8.0 million, and (iv) immaterial net charges related to several matters. 13

(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.1 million in each period), amortization expense ($17.0 million and $10.4 million), amortization of acquired inventory step-up ($0.9 million and none), and asset impairment charges ($1.0 million and $0.6 million).

(3) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.4 million and $1.8 million) and site closure costs ($0.4 million and $0.5 million).

(4) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.8 million and $0.7 million) and asset impairment charges ($13.8 million and none).

(5) For the three months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.

(7) Adjustments to charges (credit) related to legal matters, net were $7.5 million for the three months ended September 30, 2026, primarily consisting of a charge related to government investigations of $8.0 million, partially offset by immaterial net credits related to several matters. 14

(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($3.1 million and $2.9 million), amortization expense ($39.1 million and $30.5 million), amortization of acquired inventory step-up ($0.9 million and none), and asset impairment charges ($1.0 million and $0.7 million).

(3) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($6.8 million and $4.7 million) and site closure costs ($1.4 million and $1.6 million).

(4) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.2 million and $2.1 million) and asset impairment charges ($13.8 million and none).

(5) For the nine months ended September 30, 2026, the Company recognized a $6.0 million gain related to the remeasurement of contingent consideration associated with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the contingent consideration liability driven primarily by increases in the discount rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded charges related to inventory and property losses and associated cleanup, repair and remediation costs.

(7) Adjustments to charges (credit) related to legal matters, net were $16.3 million for the nine months ended September 30, 2026, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date, (ii) net charges associated with antitrust class action litigation of $7.5 million, (iii) a charge related to government investigations of $8.0 million, and (iv) immaterial net charges related to several matters. 15

(1) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of amortization expense ($18.9 million and $26.5 million) and asset impairment charges (none and $22.1 million).

(2) Adjustments for the three months ended September 30, 2026 and 2025 were comprised of stock-based compensation expense.

(3) Adjustments for the three months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.1 million in each period) and site closure costs (none and $1.7 million). 16

(1) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of amortization expense ($56.4 million and $92.0 million) and asset impairment charges (none and $22.1 million).

(2) Adjustments for the nine months ended September 30, 2026 and 2025 were comprised of stock-based compensation expense.

(3) Adjustments for the nine months ended September 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.4 million and $0.3 million) and site closure costs (none and $3.1 million). 17

(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2) Adjustments for the three months ended September 30, 2026 and 2025 were comprised of amortization expense. 18

(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2) Adjustments for the nine months ended September 30, 2026 and 2025 were comprised of amortization expense. 19

Full text with the tables
                                                                    Exhibit 99.1
                                                                                
              AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS               
                                                                                
  – Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted  
                          Loss per Share of $(0.06) –                           
                                                                                
       – Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 –       
                                                                                
                      – Updating 2026 Full Year Guidance –                      
BRIDGEWATER, NJ, November 3, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX)
(“Amneal” or the “Company”) today announced its results for the third quarter
ended September 30, 2026.

“Amneal delivered another quarter of strong, broad-based performance, enabling
us to increase our 2026 guidance once more. As we prepare to enter 2027, our
financial performance is accelerating driven by a number of key catalysts and
new launches, including Women’s Health patches, biosimilars, injectables such as
lanreotide, CREXONT ® , and BREKIYA ® autoinjector. The Kashiv integration is
proceeding well, and we are excited about the long-term growth potential in
biosimilars. With the breadth and depth of opportunities across our portfolio,
we remain highly confident in Amneal’s robust growth outlook,” said Chirag and
Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.
                                                                                
  Third Quarter 2026 Results                                                    
                                                                                
Net revenue in the third quarter of 2026 was $863 million, an increase of 10%
compared to $785 million in the third quarter of 2025. Affordable Medicines net
revenue increased 19%, driven by biosimilars, women’s health patches, and new
launches. Specialty net revenue increased 20%, driven by key branded products,
including CREXONT ® , BREKIYA ® autoinjector, and UNITHROID ® . AvKARE net
revenue decreased 17%, as expected, due to a non-recurring cardiovascular
product launch in the prior year.

Net loss attributable to Amneal Pharmaceuticals, Inc. was $22 million in the
third quarter of 2026 compared to net income of $2 million in the third quarter
of 2025 as higher revenue and gross profit were more than offset by non-
recurring acquisition and integration costs, and higher tax provision.

Adjusted EBITDA in the third quarter of 2026 was $207 million, an increase of
30% compared to the third quarter of 2025, reflecting higher revenue, higher
gross profit, and lower operating expenses.

Diluted loss per share in the third quarter of 2026 was $(0.06) compared to
diluted income per share of $0.01 for the third quarter of 2025, due to the
aforementioned factors and higher share count as a result of the Kashiv
acquisition. Adjusted diluted earnings per share in the third quarter of 2026
was $0.26, an increase of 53% compared to $0.17 for the third quarter of 2025.

The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please
refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to
non-GAAP reconciliation tables for more information.
                                       1                                        
                                                                                
  Updating 2026 Full Year Guidance                                              
                                                                                
We are increasing full year 2026 guidance for net revenue, adjusted EBITDA, and
adjusted diluted EPS. The Company is also updating operating cash flow guidance,
reflecting working capital, including higher inventory levels in key growth
areas.
                                                                                
                            Updated Guidance           Prior Guidance           
  Net revenue               $3.15 billion - $3.25      $3.10 billion - $3.20    
                            billion                    billion                  
  Adjusted EBITDA(1)        $800 million - $815        $750 million - $780      
                            million                    million                  
  Adjusted diluted          $1.04 - $1.08              $0.96 - $1.06            
  EPS(2)                                                                        
  Operating cash flow(3)    $325 million - $375        $350 million - $400      
                            million                    million                  
  Operating cash flow,      $350 million - $400        $375 million - $425      
  excluding discrete        million                    million                  
  items(4)                                                                      
  Capital                   ~$150 million              ~$150 million            
  expenditures(5)                                                               
                                                                                
(1) Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial
Measures” below.

(2) Accounts for non-controlling interest in AvKARE. Assumes approximately 340
million weighted-average diluted shares outstanding for the year ending December
31, 2026.

(3) Represents cash provided by operating activities.
(4) Excludes discrete items such as opioid settlement costs of approximately $36
million and Kashiv acquisition and integration costs of approximately $40
million.

(5) Reflects estimated capital expenditures and deposits for future acquisition
of property, plant, and equipment.
Amneal’s 2026 estimates are based on management’s current expectations,
including with respect to prescription trends, pricing levels, the timing of
future product launches, the costs incurred and benefits realized of
restructuring activities, and our long-term strategy. The Company’s financial
statements are prepared in accordance with accounting principles generally
accepted in the United States of America (“GAAP”). The Company cannot provide a
reconciliation between non-GAAP projections and the most directly comparable
measures in accordance with GAAP without unreasonable efforts because it is
unable to predict with reasonable certainty the ultimate outcome of certain
significant items required for the reconciliation. The items include, but are
not limited to, acquisition-related expenses, restructuring expenses and
benefits, asset impairments, legal settlements, and other gains and losses.
These items are uncertain, depend on various factors, and could have a material
impact on GAAP reported results.
                                                                                
  Conference Call Information                                                   
                                                                                
Amneal will host a conference call and live webcast at 8:30 am Eastern Time
today, November 3, 2026, to discuss its results. The live webcast and
presentation will be accessible through the Investor Relations section of the
Company’s website at https://investors.amneal.com. To access the call through a
conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 304152835.
A replay of the conference call will be posted shortly after the call. For a
list of toll-free international numbers, visit this website:
https://help.events.q4inc.com/eahc/international-dial-in-numbers.
                                                                                
  About Amneal                                                                  
                                                                                
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New
Jersey, is a diversified, global biopharmaceutical leader focused on expanding
access to affordable and innovative medicines. Amneal was founded in 2002 by
brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that
innovation only matters if it’s accessible. Today, Amneal has a diverse and
growing portfolio of approximately 300 complex generic, specialty and biosimilar
medicines, delivering more than 160 million prescriptions annually, primarily in
the United States. Our Affordable Medicines segment spans retail generics,
injectables, and biosimilars. Our Specialty segment provides branded treatments
in neurology, including Parkinson’s disease and migraine, and endocrinology. Our
AvKARE segment distributes pharmaceuticals and medical products to U.S. federal,
retail, and institutional customers. For additional information, please visit
amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical
facts, may be forward-looking statements (as defined in the U.S. Private
Securities Litigation Reform Act of 1995). Such forward-looking statements
include statements regarding management’s intentions, plans, beliefs,
expectations, financial results, or forecasts for the future, including among
other things: discussions of future operations; expected or estimated operating
results and financial performance; statements regarding product launches;
statements regarding our potential growth and other non-historical statements.
Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and
similar words, or the negatives thereof, are intended to identify estimates and
forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These
forward-looking statements are based on current expectations of future events,
including with respect to future market conditions, company performance and
financial results, operational investments, business prospects, new strategies
and growth initiatives, the competitive environment, and other
                                       2                                        
events. If the underlying assumptions prove inaccurate or known or unknown risks
or uncertainties materialize, actual results could vary materially from the
expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: risks related to
integrating our acquisition (the “Kashiv Acquisition”) of Kashiv BioSciences,
LLC (“Kashiv”) and realizing the anticipated benefits of the acquisition; our
ability to successfully develop, license, acquire and commercialize new products
on a timely basis; the competition we face in the pharmaceutical industry from
brand and generic drug product companies, and the impact of that competition on
our ability to set prices; our ability to obtain exclusive marketing rights for
our products; the impact of illegal distribution and sale by third parties of
counterfeit versions of our products or stolen products; the impact of negative
market perceptions of us and the safety and quality of our products; our
revenues are derived from the sales of a limited number of products, a
substantial portion of which are through a limited number of customers; the
continuing trend of consolidation of certain customer groups; the impact of
supply chain disruption; the imposition of tariffs may adversely affect our
business, results of operations and financial condition; a U.S. government
shutdown could adversely impact our regulatory, operational and financial
performance; legal, regulatory and legislative efforts by our brand competitors
to deter competition from our generic alternatives; our dependence on
information technology systems and infrastructure and the potential for
cybersecurity incidents, and risks associated with artificial intelligence; the
impact of a prolonged business interruption within our supply chain; our ability
to attract, hire and retain highly skilled personnel; risks related to federal
regulation of arrangements between manufacturers of branded and generic
products; our reliance on certain licenses to proprietary technologies from time
to time; the significant amount of resources we expend on research and
development; the risk of claims brought against us by third parties; risks
related to changes in the regulatory environment, including U.S. federal and
state laws related to government contracting, healthcare fraud abuse and health
information privacy and security and changes in such laws; changes to Food and
Drug Administration product approval requirements and review processes; the
impact of healthcare reform and changes in coverage and reimbursement levels and
funding by governmental authorities and other third-party payers; our ability to
identify, make and integrate acquisitions or investments in complementary
businesses and products on advantageous terms; our dependence on third-party
agreements for a portion of our product offerings; our potential expansion into
additional international markets subjecting us to increased regulatory,
economic, social and political uncertainties; the impact of global economic,
political or other catastrophic events; our substantial amount of indebtedness
and our ability to generate sufficient cash to service our indebtedness in the
future, and the impact of interest rate fluctuations on such indebtedness; our
obligations under a tax receivable agreement may be significant; and the high
concentration of ownership of our Class A common stock by the Amneal Group. The
forward-looking statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including under Item 1A,
“Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in
its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to
place undue reliance on any such forward-looking statements, which speak only as
of the date they are made. Forward-looking statements included herein speak only
as of the date hereof and we undertake no obligation to revise or update such
statements to reflect the occurrence of events or circumstances after the date
hereof.
                                                                                
   Non-GAAP Financial Measures                                                  
                                                                                
This release includes certain non-GAAP financial measures, including EBITDA,
adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross
margin, adjusted operating income, net debt, gross leverage, and net leverage,
which are intended as supplemental measures of the Company’s performance that
are not required by or presented in accordance with GAAP.

Management uses these non-GAAP measures internally to evaluate and manage the
Company’s operations and to better understand its business because they
facilitate a comparative assessment of the Company’s operating performance
relative to its performance based on results calculated under GAAP. These non-
GAAP measures also isolate the effects of some items that vary from period to
period without any correlation to core operating performance and eliminate
certain charges that management believes do not reflect the Company’s operations
and underlying operational performance. The compensation committee of the
Company’s board of directors also uses certain of these measures to evaluate
management’s performance and set its compensation. The Company believes that
these non-GAAP measures also provide useful information to investors regarding
certain financial and business trends relating to the Company’s financial
condition and operating results and facilitate an evaluation of the financial
performance of the Company and its operations on a consistent basis. Providing
this information therefore allows investors to make independent assessments of
the Company’s financial performance, results of operations, cash flows, net
leverage and trends while viewing the information through the eyes of
management.

These non-GAAP measures are subject to limitations. The non-GAAP measures
presented in this release may not be comparable to similarly titled measures
used by other companies because other companies may not calculate one or more in
the same manner. Additionally, the non-GAAP performance measures exclude
significant expenses and income that are required by GAAP to be recorded in the
Company’s financial statements; do not reflect changes in, or cash requirements
for, working
                                       3                                        
capital needs; and do not reflect interest expense, or the requirements
necessary to service interest or principal payments on debt. Further, our
historical adjusted results are not intended to project our adjusted results of
operations or financial position for any future period. To compensate for these
limitations, management presents and considers these non-GAAP measures in
conjunction with the Company’s GAAP results; no non-GAAP measure should be
considered in isolation from or as an alternative to any measure determined in
accordance with GAAP. Readers should review the reconciliations included below,
and should not rely on any single financial measure to evaluate the Company’s
business.

A reconciliation of each historical non-GAAP measure to the most directly
comparable GAAP measure is set forth below.
                                                                                
  Contact                                                                       
                                                                                
Anthony DiMeo
VP, Investor Relations

[email protected]
                                       4                                        
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                     Consolidated Statements of Operations                      
                                                                                
              (unaudited; in thousands, except per share amounts)               
                                                                                
                     Three                              Nine                    
                    Months                            Months                    
                     Ended                             Ended                    
                  Septemb…                           Septem…                    
            2026       30,    2025             2026      30,    2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net       $      862,684    $     784,513    $     2,381,…    $     2,204,4…  
  reven…                                                                        
  Cost                                                                          
  of               528,566          510,539          1,392,…          1,388,3…  
  goods                                                                         
  sold                                                                          
  Gross            334,118          273,974          988,739           816,118  
  profit                                                                        
  Selli…                                                                        
  gener…           139,645          137,815          427,227           380,369  
  and                                                                           
  admin…                                                                        
  Resea…                                                                        
  and               68,374           63,352          145,774           151,356  
  devel…                                                                        
  Intel…                                                                        
  prope…                                                                        
  legal              2,193            2,437            5,822             6,221  
  devel…                                                                        
  expen…                                                                        
  Acqui…                                                                        
  and               22,320                —           35,073                 —  
  integ…                                                                        
  costs                                                                         
  Restr…                                                                        
  and                  936              143            2,140             1,738  
  other                                                                         
  charg…                                                                        
  Change                                                                        
  in                                                                            
  fair                                                                          
  value             -6,000                —           -6,000                 —  
  of                                                                            
  conti…                                                                        
  consi…                                                                        
  Charg…                                                                        
  for                                                                           
  prope…                                                                        
  losses             5,369                —            5,369                 —  
  and                                                                           
  assoc…                                                                        
  expen…                                                                        
  Charg…                                                                        
  (cred…                                                                        
  relat…                                                                        
  to                 6,497                —           15,248              -390  
  legal                                                                         
  matte…                                                                        
  net                                                                           
  Other                                                                         
  opera…              -631             -117           -8,870            -5,239  
  income                                                                        
  Opera…            95,415           70,344          366,956           282,063  
  income                                                                        
  Other                                                                         
  (expe…                                                                        
  incom…                                                                        
  Inter…                                                                        
  expen…           -58,913          -62,814          -167,3…          -184,854  
  net                                                                           
  Forei…                                                                        
  excha…                                                                        
  (loss)            -3,174           -3,431          -12,924             9,072  
  gain,                                                                         
  net                                                                           
  Loss                                                                          
  on                -5,760          -31,365           -9,270           -31,365  
  refin…                                                                        
  (Incr…                                                                        
  decre…                                                                        
  in tax           -12,992           20,808          -13,098             5,701  
  recei…                                                                        
  agree…                                                                        
  liabi…                                                                        
  Other                                                                         
  incom…               481            1,235            1,876             3,357  
  net                                                                           
  Total                                                                         
  other            -80,358          -75,567          -200,7…          -198,089  
  expen…                                                                        
  net                                                                           
  Income                                                                        
  (loss)                                                                        
  before            15,057           -5,223          166,223            83,974  
  income                                                                        
  taxes                                                                         
  Provi…                                                                        
  for                                                                           
  (bene…             2,751          -23,355            6,303             5,614  
  from)                                                                         
  income                                                                        
  taxes                                                                         
  Net               12,306           18,132          159,920            78,360  
  income                                                                        
  Less:                                                                         
  Net                                                                           
  income                                                                        
  attri…           -19,762          -15,763          -47,458           -41,379  
  to                                                                            
  non-c…                                                                        
  inter…                                                                        
  Net                                                                           
  (loss)                                                                        
  income                                                                        
  attri…                                                                        
  to                                                                            
  Amneal                                                                        
  Pharm…            -7,456            2,369          112,462            36,981  
  Inc.                                                                          
  before                                                                        
  accre…                                                                        
  of                                                                            
  redee…                                                                        
  non-c…                                                                        
  inter…                                                                        
  Accre…                                                                        
  of                                                                            
  redee…           -14,239                —          -14,239                 —  
  non-c…                                                                        
  inter…                                                                        
  Net                                                                           
  (loss)                                                                        
  income                                                                        
  attri…    $      -21,695    $       2,369    $      98,223    $       36,981  
  to                                                                            
  Amneal                                                                        
  Pharm…                                                                        
  Inc.                                                                          
  Net                                                                           
  income                                                                        
  per                                                                           
  share                                                                         
  attri…                                                                        
  to                                                                            
  Amneal                                                                        
  Pharm…                                                                        
  Inc.’s                                                                        
  Class                                                                         
  A                                                                             
  common                                                                        
  stock…                                                                        
                                                                                
  Basic     $        -0.06    $        0.01    $        0.30    $         0.12  
  Dilut…    $        -0.06    $        0.01    $        0.29    $         0.11  
  Weigh…                                                                        
  common                                                                        
  shares                                                                        
  outst…                                                                        
  Basic            335,733          314,168          323,724           312,998  
  Dilut…           335,733          324,754          335,233           323,704  
                                                                                
                                       5                                        
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                           (unaudited; in thousands)                            
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash equivalents      $             157,399    $            282,029  
  Restricted cash                               14,174                  28,842  
  Trade accounts receivable,                 1,016,844                 895,143  
  net                                                                           
  Inventories                                  707,956                 606,302  
  Prepaid expenses and other                                                    
  current                                      196,769                  98,395  
  assets                                                                        
  Related party receivables                      1,876                     470  
  Total current assets                       2,095,018               1,911,181  
  Property, plant and                          572,634                 442,950  
  equipment, net                                                                
  Goodwill and intangible                    2,323,728               1,158,968  
  assets, net                                                                   
  Operating lease                               69,760                  38,832  
  right-of-use assets                                                           
  Operating lease                                                               
  right-of-use assets -                         20,019                  15,216  
  related party                                                                 
  Financing lease                               63,255                  53,328  
  right-of-use assets                                                           
  Other assets                                 122,807                  57,805  
  Total assets                   $           5,267,221    $          3,678,280  
  Liabilities and                                                               
  Stockholders’ Equity                                                          
  (Deficiency)                                                                  
  Current liabilities:                                                          
  Accounts payable and           $             788,831    $            761,316  
  accrued expenses                                                              
  Current portion of                                                            
  liabilities for legal                         27,534                  43,256  
  matters                                                                       
  Revolving credit facility                    180,000                       —  
  Current portion of                            23,933                   6,761  
  long-term debt, net                                                           
  Current portion of                                                            
  operating lease                               14,417                   8,668  
  liabilities                                                                   
  Current portion of                                                            
  operating lease                                3,398                   2,705  
  liabilities - related party                                                   
  Current portion of                                                            
  financing lease                                3,811                   3,442  
  liabilities                                                                   
  Related party payables -                      18,913                  55,485  
  short term                                                                    
  Contingent consideration -                                                    
  related party                                 59,000                       —  
  - short term                                                                  
  Total current liabilities                  1,119,837                 881,633  
  Long-term debt, net                        2,915,501               2,565,115  
  Operating lease liabilities                   59,612                  33,233  
  Operating lease liabilities                                                   
  - related                                     16,635                  14,195  
  party                                                                         
  Financing lease liabilities                   65,588                  54,927  
  Related party payables -                      15,878                  19,132  
  long term                                                                     
  Liabilities for legal                                                         
  matters - long                                71,663                  71,819  
  term                                                                          
  Contingent consideration -                                                    
  related party                                324,000                       —  
  - long term                                                                   
  Other long-term liabilities                   37,797                  32,263  
  Total long-term liabilities                3,506,674               2,790,684  
  Redeemable non-controlling                   109,453                  77,292  
  interests                                                                     
  Total stockholders’ equity                   531,257                 -71,329  
  (deficiency)                                                                  
  Total liabilities and                                                         
  stockholders’                  $           5,267,221    $          3,678,280  
  equity (deficiency)                                                           
                                                                                
                                       6                                        
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                     Consolidated Statements of Cash Flows                      
                                                                                
                           (unaudited; in thousands)                            
                                                                                
  Cash flows from         Nine Months Ended                                     
  operating               September 30,                                         
  activities:             2026                                2025              
 ────────────────────────────────────────────────────────────────────────────── 
  Net income              $                        159,920    $         78,360  
  Adjustments to                                                                
  reconcile net income                                                          
  to                                                                            
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Depreciation and                                 144,250             174,345  
  amortization                                                                  
  Unrealized foreign                                13,571              -8,606  
  currency loss (gain)                                                          
  Amortization of debt                                                          
  issuance costs and                                12,141              18,716  
  discount                                                                      
  Reclassification of                                8,730              -1,713  
  cash flow hedge                                                               
  Loss on refinancing                                9,270              31,365  
  Intangible asset                                     975              22,784  
  impairment charges                                                            
  Research and                                                                  
  development                                       13,832                   —  
  equipment                                                                     
  impairment charges                                                            
  Non-cash property                                  5,035                   —  
  losses                                                                        
  Change in fair value                                                          
  of contingent                                     -6,000                   —  
  consideration                                                                 
  Stock-based                                       29,723              23,751  
  compensation                                                                  
  Inventory provision                               64,981              59,326  
  Other operating                                                               
  charges and credits,                               4,689               3,575  
  net                                                                           
  Changes in assets                                                             
  and liabilities:                                                              
  Trade accounts                                  -122,423            -110,228  
  receivable, net                                                               
  Inventories                                     -158,346             -66,846  
  Prepaid expenses,                                                             
  other current assets                            -113,073             -20,173  
  and other assets                                                              
  Related party                                        203                -830  
  receivables                                                                   
  Accounts payable,                                                             
  accrued expenses and                              17,590               2,744  
  other liabilities                                                             
  Related party                                    -34,756               3,107  
  payables                                                                      
  Net cash provided by                                                          
  operating                                         50,312             209,677  
  activities                                                                    
  Cash flows from                                                               
  investing                                                                     
  activities:                                                                   
  Acquisition of                                                                
  Kashiv, net of cash                                                           
  and                                             -421,047                   —  
  restricted cash                                                               
  acquired                                                                      
  Purchases of                                                                  
  property, plant and                              -70,659             -48,290  
  equipment                                                                     
  Acquisition of                                   -96,603             -12,514  
  intangible assets                                                             
  Deposits for future                                                           
  acquisition of                                   -28,376              -7,384  
  property, plant and                                                           
  equipment                                                                     
  Proceeds from sale                                                            
  of property, plant                                     —               1,379  
  and equipment                                                                 
  Net cash used in                                -616,685             -66,809  
  investing activities                                                          
  Cash flows from                                                               
  financing                                                                     
  activities:                                                                   
  Payments of                                                                   
  principal on debt,                                                            
  revolving                                       -293,172          -2,805,384  
  credit facilities,                                                            
  financing leases and                                                          
  other                                                                         
  Proceeds from                                    529,853           2,694,750  
  issuance of debt                                                              
  Payments of deferred                                                          
  financing and                                     -7,549             -74,973  
  refinancing costs                                                             
  Borrowings on                                                                 
  revolving credit                                 280,000             218,000  
  facilities                                                                    
  Proceeds from                                                                 
  exercise of stock                                    516               1,407  
  options                                                                       
  Employee payroll tax                                                          
  withholding on                                                                
  restricted stock                                 -44,696             -21,957  
  unit and performance                                                          
  stock unit vesting                                                            
  Tax and other                                                                 
  distributions to                                 -29,571             -38,825  
  non-controlling                                                               
  interests                                                                     
  Proceeds from                                        510               5,572  
  alliance party                                                                
  Acquisition of                                                                
  non-controlling                                     -400                   —  
  interest                                                                      
  Net cash provided by                                                          
  (used in) financing                              435,491             -21,410  
  activities                                                                    
  Effect of foreign                                                             
  exchange rate on                                  -1,804              -1,471  
  cash                                                                          
  Net decrease in                                                               
  cash, cash                                      -132,686             119,987  
  equivalents,                                                                  
  and restricted cash                                                           
  Cash, cash                                                                    
  equivalents, and                                                              
  restricted                                       312,939             118,420  
  cash - beginning of                                                           
  period                                                                        
  Cash, cash                                                                    
  equivalents, and        $                        180,253    $        238,407  
  restricted                                                                    
  cash - end of period                                                          
  Cash and cash                                                                 
  equivalents - end of    $                        157,399    $        201,249  
  period                                                                        
  Restricted cash -                                 14,174              34,727  
  end of period                                                                 
  Long-term restricted                                                          
  cash included in                                   8,680               2,431  
  other assets - end                                                            
  of period                                                                     
  Cash, cash                                                                    
  equivalents, and        $                        180,253    $        238,407  
  restricted                                                                    
  cash - end of period                                                          
                                                                                
                                       7                                        
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                            Non-GAAP Reconciliations                            
                                                                                
                           (unaudited, in thousands)                            
                                                                                
           Reconciliation of Net Income to EBITDA and Adjusted EBITDA           
                                                                                
                Thr…                         Nine                               
                Mon…                         Mon…                         Year  
                End…                         End…                         End…  
                Sep…                         Sep…                         Dec…  
          2026   30,    2025           2026   30,    2025           2025   31,  
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $     12,…    $     18,1…    $     159…    $     78,3…    $     127…  
  inc…                                                                          
  Adj…                                                                          
  to                                                                            
  add:                                                                          
  Int…                                                                          
  exp…          58,…          62,8…          167…          184,…          241…  
  net                                                                           
  Pro…                                                                          
  for                                                                           
  (be…          2,7…          -23,…          6,3…          5,614          11,…  
  fro…                                                                          
  inc…                                                                          
  tax…                                                                          
  Dep…                                                                          
  and           53,…          54,0…          144…          174,…          223…  
  amo…                                                                          
  EBI…    $     127…    $     111,…    $     477…    $     443,…    $     603…  
  (No…                                                                          
  Adj…                                                                          
  to                                                                            
  add                                                                           
  (de…                                                                          
  Sto…                                                                          
  com…          10,…          8,219          29,…          23,6…          31,…  
  exp…                                                                          
  Acq…                                                                          
  site                                                                          
  clo…                                                                          
  and           22,…          2,318          36,…          4,762          5,3…  
  idle                                                                          
  fac…                                                                          
  exp…                                                                          
  Res…                                                                          
  and            890            143          1,3…          1,738          4,2…  
  oth…                                                                          
  cha…                                                                          
  Loss                                                                          
  on            5,7…          31,3…          9,2…          31,3…          31,…  
  ref…                                                                          
  Amo…                                                                          
  of                                                                            
  acq…           946              —           946              —             —  
  inv…                                                                          
  ste…                                                                          
  Cha…                                                                          
  (cr…                                                                          
  rel…                                                                          
  to            7,5…              —          16,…           -390          -390  
  leg…                                                                          
  mat…                                                                          
  net…                                                                          
  Ass…                                                                          
  imp…          14,…          22,7…          14,…          22,8…          23,…  
  cha…                                                                          
  For…                                                                          
  exc…          3,1…          3,431          12,…          -9,0…          -7,…  
  loss                                                                          
  (ga…                                                                          
  Cha…                                                                          
  in                                                                            
  fair                                                                          
  val…          -6,…              —          -6,…              —             —  
  of                                                                            
  con…                                                                          
  con…                                                                          
  Cha…                                                                          
  for                                                                           
  pro…                                                                          
  los…          5,3…              —          5,3…              —             —  
  and                                                                           
  ass…                                                                          
  exp…                                                                          
  Inc…                                                                          
  (de…                                                                          
  in                                                                            
  tax           12,…          -20,…          13,…          -5,7…          6,5…  
  rec…                                                                          
  agr…                                                                          
  lia…                                                                          
  Oth…          1,1…            459          3,4…            829          -9,…  
  Adj…                                                                          
  EBI…    $     207…    $     159,…    $     615…    $     513,…    $     688…  
  (No…                                                                          
                                                                                
                                       8                                        
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                            Non-GAAP Reconciliations                            
                                                                                
                          (unaudited, $ in thousands)                           
                                                                                
                    Calculation of Net Debt and Net Leverage                    
                                                                                
                                                                                
                              September                         December        
                               30, 2026                         31, 2025        
 ────────────────────────────────────────────────────────────────────────────── 
  Term Loan     $             2,434,263          $             2,094,750        
  Due 2032                                                                      
  Senior                                                                        
  Notes Due                     600,000                          600,000        
  2032                                                                          
  2025                                                                          
  Revolving                     180,000                                —        
  Credit                                                                        
  Facility                                                                      
  Kashiv                                                                        
  Rupee Term                     16,484                                —        
  Loan                                                                          
  Facility                                                                      
  Gross         $             3,230,747          $             2,694,750        
  debt(8)                                                                       
  Less: Cash                                                                    
  and cash                      157,399                          282,029        
  equivalen…                                                                    
  Net debt      $             3,073,348          $             2,412,721        
  (Non-GAAP…                                                                    
                Adjusted                         Adjusted                       
                EBITDA                           EBITDA                         
                (Non-GAAP)                       (Non-GAAP)                     
  Year ended                                                                    
  December      $               688,415          $               688,415        
  31, 2025                                                                      
  Less:                                                                         
  Nine                                                                          
  months                        513,213                                         
  ended                                                                         
  September                                                                     
  30, 2025                                                                      
  Add:                                                                          
  Nine                                                                          
  months                        615,489                                         
  ended                                                                         
  September                                                                     
  30, 2026                                                                      
  Last                                                                          
  twelve                                                                        
  months                                                                        
  ended         $               790,691                                         
  September                                                                     
  30,                                                                           
  2026                                                                          
                Last Twelve                                                     
                Months                           Year Ended                     
                Ended                            December                       
                September                        31, 2025                       
                30, 2026                                                        
  Gross                                                                         
  leverage                               4.1x                             3.9x  
  (Non-GAAP…                                                                    
  Net                                                                           
  leverage                               3.9x                             3.5x  
  (Non-GAAP…                                                                    
                                                                                
                                       9                                        
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                            Non-GAAP Reconciliations                            
                                                                                
              (unaudited; in thousands, except per share amounts)               
                                                                                
Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted 
                           Diluted Earnings Per Share                           
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net        $      12,306    $      18,132    $      159,920    $      78,360  
  income                                                                        
  Adjust…                                                                       
  to add                                                                        
  (deduc…                                                                       
  Non-ca…            7,098            9,163            20,779           16,908  
  intere…                                                                       
  GAAP                                                                          
  provis…                                                                       
  for                                                                           
  (benef…            2,751          -23,355             6,303            5,614  
  from)                                                                         
  income                                                                        
  taxes                                                                         
  Amorti…           37,671           38,647           100,696          127,741  
  Stock-…                                                                       
  compen…           10,515            8,219            29,723           23,621  
  expense                                                                       
  Acquis…                                                                       
  site                                                                          
  closur…                                                                       
  and               22,745            2,284            36,503            4,700  
  idle                                                                          
  facili…                                                                       
  expens…                                                                       
  Restru…                                                                       
  and                  890              143             1,389            1,731  
  other                                                                         
  charges                                                                       
  Loss on            5,760           31,365             9,270           31,365  
  refina…                                                                       
  Amorti…                                                                       
  of                                                                            
  acquir…              946                —               946                —  
  invent…                                                                       
  step-up                                                                       
  Charges                                                                       
  (credi…                                                                       
  related                                                                       
  to                                                                            
  legal              8,585                —            19,152             -390  
  matter…                                                                       
  includ…                                                                       
  intere…                                                                       
  net(3)                                                                        
  Asset                                                                         
  impair…           14,809           22,784            14,809           22,888  
  charge…                                                                       
  Change                                                                        
  in fair                                                                       
  value             -6,000                —            -6,000                —  
  of                                                                            
  contin…                                                                       
  consid…                                                                       
  Charges                                                                       
  for                                                                           
  proper…                                                                       
  losses             5,369                —             5,369                —  
  and                                                                           
  associ…                                                                       
  expens…                                                                       
  Increa…                                                                       
  (decre…                                                                       
  in tax            12,992          -20,808            13,098           -5,701  
  receiv…                                                                       
  agreem…                                                                       
  liabil…                                                                       
  Other              1,100              459             3,417              839  
  Provis…                                                                       
  for              -28,270          -16,868           -90,030          -65,722  
  income                                                                        
  taxes(…                                                                       
  Net                                                                           
  income                                                                        
  attrib…          -19,762          -15,763           -47,458          -41,379  
  to                                                                            
  non-co…                                                                       
  intere…                                                                       
  Adjust…                                                                       
  net        $      89,505    $      54,402    $      277,886    $     200,575  
  income                                                                        
  (Non-G…                                                                       
  Weight…                                                                       
  diluted          348,448          324,754           335,233          323,704  
  shares                                                                        
  outsta…                                                                       
  Diluted                                                                       
  (loss)                                                                        
  earnin…    $       -0.06    $        0.01    $         0.29    $        0.11  
  per                                                                           
  share                                                                         
  (GAAP)                                                                        
  Adjust…                                                                       
  diluted                                                                       
  earnin…    $        0.26    $        0.17    $         0.83    $        0.62  
  per                                                                           
  share                                                                         
  (Non-G…                                                                       
                                                                                
                                       10                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                            Non-GAAP Reconciliations                            
                                                                                
                                  (unaudited)                                   
                                                                                
                   Explanations for Non-GAAP Reconciliations                    
                                                                                
(1) Acquisition, site closure, and idle facility expenses for the three and nine
months ended September 30, 2026 primarily included acquisition costs associated
with the acquisition of Kashiv and rent for vacated properties. Acquisition,
site closure, and idle facility expenses for the three and nine months ended
September 30, 2025 and year ended December 31, 2025 primarily included costs
related to a planned facility closure and rent for vacated properties.

(2) Loss on refinancing for the three and nine months ended September 30, 2026
was primarily comprised of debt issuance costs and the write-off of unamortized
debt issuance costs. In February 2026, the Company entered into a repricing
amendment for the Company’s Term Loan Due 2032 (the “February 2026 Repricing
Amendment”), which reduced the applicable interest rate margins on such term
loan. In August 2026, the Company entered into another repricing amendment for
the Company’s Term Loan Due 2032 (the “August 2026 Repricing Amendment”), which
further reduced the applicable interest rate margins on such term loan. Also in
August 2026, the Company borrowed an additional $350.0 million under Amendment
No. 4 to the Company’s Term Loan Credit Agreement (the “Incremental Term Loans”)
to fund a portion of the cash consideration for the Kashiv Acquisition. The loss
for the three months ended September 30, 2026 primarily reflects costs
associated with the August 2026 Repricing Amendment and the Incremental Term
Loans, while the loss for the nine months ended September 30, 2026 primarily
reflects costs associated with the February 2026 Repricing Amendment, the August
2026 Repricing Amendment and the Incremental Term Loans. For 2025, loss on
refinancing was primarily comprised of debt issuance costs associated with the
portion of the Term Loan Due 2028 that was modified as part of the Company’s
debt refinancing on August 1, 2025. Refer to Not e 14. Debt in the Company’s
2025 Annual Report on Form 10-K for information about the Company’s debt as of
December 31, 2025.

(3) For the three months ended September 30, 2026, charges related to legal
matters, net were $7.5 million, primarily consisting of a charge related to
government investigations of $8.0 million, partially offset by immaterial net
credits related to several matters. For the nine months ended September 30,
2026, charges related to legal matters, net were $16.3 million , primarily
consisting of (i) a $21.2 million charge associated with certain states electing
a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement
Agreement, partially offset by a $20.8 million discount recorded on the expected
settlement payments as of the agreement’s effective date, (ii) net charges
associated with antitrust class action litigation of $7.5 million, (iii) a
charge related to government investigations of $8.0 million, and (iv) immaterial
net charges related to several matters. For the three and nine months ended
September 30, 2026, charges related to legal matters, including interest, net
also included interest expense associated with the Nationwide Opioids Settlement
Agreement. For additional information regarding the Nationwide Opioids
Settlement Agreement and antitrust class action litigation, refer to Note 16.
Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2026.

(4) For the three and nine months ended September 30, 2026, impairment charges
related to certain equipment used in research and development activities as a
result of a change in the expected future utilization of the assets as well as
an immaterial intangible asset impairment. For 2025, asset impairment charges
primarily related to a Specialty segment product right for which the Company
significantly reduced the cash flow forecast after receipt of a complete
response letter dated July 22, 2025 from the U.S. Food and Drug Administration
regarding a supplemental new drug application.

(5) During the three and nine months ended September 30, 2026, the Company
recognized a $6.0 million gain related to the remeasurement of contingent
consideration associated with the Kashiv Acquisition. The gain reflects the
periodic remeasurement of the contingent consideration liability driven
primarily by increases in the discount rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.

(7) For the year ended December 31, 2025, the caption “other” primarily reflects
a non-recurring, non-operating, non-cash gain.

(8) Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for
additional information about the Company’s debt. On August 10, 2026, the Company
borrowed an additional $350.0 million under its Term Loan Due 2032, with
substantially the same terms as the existing term loans, primarily to finance a
portion of the cash consideration for the Kashiv Acquisition. Additionally, in
connection with the Kashiv Acquisition, the Company assumed the Kashiv Rupee
Term Loan Facility. The Company repaid the facility in full and terminated it on
October 1, 2026.

(9) Net debt was calculated as the total outstanding principal on the Company’s
debt less cash and cash equivalents.

(10) Gross leverage was calculated by dividing gross debt as of September 30,
2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended
September 30, 2026 and year ended December 31, 2025, respectively.

(11) Net leverage was calculated by dividing net debt as of September 30, 2026
and December 31, 2025 by adjusted EBITDA for the last twelve months ended
September 30, 2026 and year ended December 31, 2025, respectively.

(12) The non-GAAP effective tax rates for the three and nine months ended
September 30, 2026 were 24.0% and 24.5%, respectively. The non-GAAP effective
tax rates for the three and nine months ended September 30, 2025 were 23.7% and
24.7%, respectively.

(13) Weighted-average diluted shares outstanding for the three and nine months
ended September 30, 2026 and 2025 consisted of fully diluted Class A common
stock (inclusive of the effect of dilutive securities).
                                       11                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                            Non-GAAP Reconciliations                            
                                                                                
                          (unaudited, $ in thousands)                           
                                                                                
       Reconciliation of Consolidated GAAP to Non-GAAP Operating Results        
                                                                                
           T…                                   T…                              
           M…                                   M…                              
           E…                                   E…                              
           S…                                   S…                              
           3…                                   3…                              
           2…                                   2…                              
 ────────────────────────────────────────────────────────────────────────────── 
       As           A…        N…           As            Ad…        No…         
       R…                                  Re…                                  
  …    $   8…       $    —    $   8…       $    7…       $     —    $    7…     
  …                                                                             
  …                                                                             
  …        5…           -…        4…            5…            -…         4…     
  …                                                                             
  …                                                                             
  …        3…           3…        3…            2…            6…         3…     
  …                                                                             
  …                                                                             
  …        3…  %                  4…  %         3…  %                    4…  %  
  %                                                                             
  …                                                                             
  …        1…           -…        1…            1…            -…         1…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        6…           -…        5…            6…            -…         6…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…            —        2…            2…             —         2…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…           -…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …        9…           -…        46            1…            -…          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…           6…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…           -…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        6…           -…        -…             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…            —        -…            -…             —         -…     
  …                                                                             
  …    $   9…       $   9…    $   1…       $    7…       $    7…    $    1…     
  …                                                                             
                                                                                
(1) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($1.1 million
and $0.9 million), amortization expense ($36.0 million and $36.9 million),
amortization of acquired inventory step-up ($0.9 million and none), and asset
impairment charges ($1.0 million and $22.8 million).

(2) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($8.6 million
and $6.5 million), amortization expense ($2.6 million and $2.7 million), site
closure costs ($0.4 million and $0.6 million), and other ($1.4 million and $1.3
million).

(3) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($0.9 million
and $0.7 million), asset impairment charges ($13.8 million and none), and site
closure costs (none and $1.8 million).

(4) Acquisition and integration costs for the three months ended September 30,
2026 were primarily related to professional services fees (e.g., investment
banking, legal, due diligence, financial advisory, accounting, and consulting)
associated with the acquisition and integration of Kashiv.

(5) During the three months ended September 30, 2026, the Company recognized a
$6.0 million gain related to the remeasurement of contingent consideration
associated with the Kashiv Acquisition. The gain reflects the periodic
remeasurement of the contingent consideration liability driven primarily by
increases in the discount rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.

(7) Adjustments to charges (credit) related to legal matters, net were $7.5
million for the three months ended September 30, 2026, primarily consisting of a
charge related to government investigations of $8.0 million, partially offset by
immaterial net credits related to several matters.
                                       12                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                            Non-GAAP Reconciliations                            
                                                                                
                          (unaudited, $ in thousands)                           
                                                                                
       Reconciliation of Consolidated GAAP to Non-GAAP Operating Results        
                                                                                
           N…                                  Ni…                              
           M…                                  Mo…                              
           E…                                  En…                              
           S…                                  Se…                              
           3…                                  30,                              
           2…                                  20…                              
 ────────────────────────────────────────────────────────────────────────────── 
       As           A…        N…           As            A…         N…          
       R…                                  R…                                   
  …    $   2…       $    —    $   2…       $   2,…       $     —    $   2,…     
  …                                                                             
  …                                                                             
  …        1…           -…        1…           1,…           -1…        1,…     
  …                                                                             
  …                                                                             
  …        9…           1…        1…           81…           14…        96…     
  …                                                                             
  …                                                                             
  …        4…  %                  4…  %        37…  %                   43…  %  
  %                                                                             
  …                                                                             
  …        4…           -…        3…           38…           -3…        34…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           -…        1…           15…           -5…        14…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…            —        5…           6,…             —        6,…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…           -…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…           -…        7…           1,…           -1…          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…           6…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…           -…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           -…        -…           -3…           390          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…            —        -…           -5…             —        -5…     
  …                                                                             
  …    $   3…       $   2…    $   5…       $   28…       $   18…    $   46…     
  …                                                                             
                                                                                
(1) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($3.1 million
and $2.8 million), amortization expense ($95.6 million and $122.5 million),
amortization of acquired inventory step-up ($0.9 million and none), and asset
impairment charges ($1.0 million and $22.9 million).

(2) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($24.2 million
and $18.4 million), amortization expense ($7.9 million and $8.1 million), site
closure costs ($1.4 million and $1.6 million), and other ($4.6 million and $4.0
million).

(3) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($2.5 million
and $2.4 million), asset impairment charges ($13.8 million and none), and site
closure costs (none and $3.2 million).

(4) Acquisition and integration costs for the nine months ended September 30,
2026 were primarily related to professional services fees (e.g., investment
banking, legal, due diligence, financial advisory, accounting, and consulting)
associated with the acquisition and integration of Kashiv.

(5) During the nine months ended September 30, 2026, the Company recognized a
$6.0 million gain related to the remeasurement of contingent consideration
associated with the Kashiv Acquisition. The gain reflects the periodic
remeasurement of the contingent consideration liability driven primarily by
increases in the discount rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.

(7) Adjustments to charges (credit) related to legal matters, net were $16.3
million for the nine months ended September 30, 2026, primarily consisting of
(i) a $21.2 million charge associated with certain states electing a 25% cash
conversion in lieu of product under the Nationwide Opioids Settlement Agreement,
partially offset by a $20.8 million discount recorded on the expected settlement
payments as of the agreement’s effective date, (ii) net charges associated with
antitrust class action litigation of $7.5 million, (iii) a charge related to
government investigations of $8.0 million, and (iv) immaterial net charges
related to several matters.
                                       13                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                          Affordable Medicines Segment                          
                                                                                
                                                                                
              Reconciliation of GAAP to Non-GAAP Operating Results              
                                                                                
                                      (1)                                       
                                                                                
                          (unaudited; $ in thousands)                           
                                                                                
           T…                                   T…                              
           M…                                   M…                              
           E…                                   E…                              
           S…                                   S…                              
           3…                                   3…                              
           2…                                   2…                              
 ────────────────────────────────────────────────────────────────────────────── 
       As           A…        N…           As            Ad…        No…         
       R…                                  Re…                                  
  …    $   5…       $    —    $   5…       $    4…       $     —    $    4…     
  …                                                                             
  …                                                                             
  …        3…           -…        3…            2…            -…         2…     
  …                                                                             
  …                                                                             
  …        1…           2…        2…            1…            1…         1…     
  …                                                                             
  …                                                                             
  …        3…  %                  3…  %         3…  %                    4…  %  
  %                                                                             
  …                                                                             
  …        3…           -…        2…            3…            -…         3…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        6…           -…        4…            5…            -…         5…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        2…            —        2…            2…             —         2…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        8…           -…         —            90            -…          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…           6…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…           -…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…           -…        -…             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…            —        -…            -…             —         -…     
  …                                                                             
  …    $   9…       $   4…    $   1…       $    8…       $    1…    $    1…     
  …                                                                             
                                                                                
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal
products by AvKARE were included in our Affordable Medicines segment.

(2) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($1.1 million
in each period), amortization expense ($17.0 million and $10.4 million),
amortization of acquired inventory step-up ($0.9 million and none), and asset
impairment charges ($1.0 million and $0.6 million).

(3) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($2.4 million
and $1.8 million) and site closure costs ($0.4 million and $0.5 million).

(4) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($0.8 million
and $0.7 million) and asset impairment charges ($13.8 million and none).

(5) For the three months ended September 30, 2026, the Company recognized a $6.0
million gain related to the remeasurement of contingent consideration associated
with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the
contingent consideration liability driven primarily by increases in the discount
rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.

(7) Adjustments to charges (credit) related to legal matters, net were $7.5
million for the three months ended September 30, 2026, primarily consisting of a
charge related to government investigations of $8.0 million, partially offset by
immaterial net credits related to several matters.
                                       14                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                          Affordable Medicines Segment                          
                                                                                
                                                                                
              Reconciliation of GAAP to Non-GAAP Operating Results              
                                                                                
                                      (1)                                       
                                                                                
                          (unaudited; $ in thousands)                           
                                                                                
           N…                                  N…                               
           M…                                  M…                               
           E…                                  E…                               
           S…                                  S…                               
           3…                                  3…                               
           2…                                  2…                               
 ────────────────────────────────────────────────────────────────────────────── 
       As           A…        N…           As           A…         N…           
       R…                                  R…                                   
  …    $   1…       $    —    $   1…       $   1…       $     —    $   1,…      
  …                                                                             
  …                                                                             
  …        8…           -…        8…           7…           -3…        74…      
  …                                                                             
  …                                                                             
  …        5…           4…        6…           5…           34…        56…      
  …                                                                             
  …                                                                             
  …        4…  %                  4…  %        4…  %                   43…   %  
  %                                                                             
  …                                                                             
  …        1…           -…        1…           1…           -6…        98…      
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           -…        1…           1…           -2…        12…      
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…            —        5…           6…             —        6,…      
  …                                                                             
  …                                                                             
  …                                                                             
  …        8…           -…         —           7…           -7…          —      
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…           6…         —            —             —          —      
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        5…           -…         —            —             —          —      
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           -…        -…           -…           390          —      
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…            —        -…           -…             —        -5…      
  …                                                                             
  …    $   3…       $   8…    $   4…       $   2…       $   42…    $        3…  
  …                                                                             
                                                                                
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal
products by AvKARE were included in our Affordable Medicines segment.

(2) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($3.1 million
and $2.9 million), amortization expense ($39.1 million and $30.5 million),
amortization of acquired inventory step-up ($0.9 million and none), and asset
impairment charges ($1.0 million and $0.7 million).

(3) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($6.8 million
and $4.7 million) and site closure costs ($1.4 million and $1.6 million).

(4) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($2.2 million
and $2.1 million) and asset impairment charges ($13.8 million and none).

(5) For the nine months ended September 30, 2026, the Company recognized a $6.0
million gain related to the remeasurement of contingent consideration associated
with the Kashiv Acquisition. The gain reflects the periodic remeasurement of the
contingent consideration liability driven primarily by increases in the discount
rate subsequent to the acquisition date.

(6) During the third week of July 2026, severe rain caused water damage to one
of the Company’s facilities in India. Operations at this facility were
temporarily suspended while the Company assessed the damage, completed
remediation and repair activities, and restored operations. The Company
concluded that certain property and equipment and inventory were damaged. The
Company also incurred costs related to cleanup, repair and remediation.
Accordingly, the Company recorded charges related to inventory and property
losses and associated cleanup, repair and remediation costs.

(7) Adjustments to charges (credit) related to legal matters, net were $16.3
million for the nine months ended September 30, 2026, primarily consisting of
(i) a $21.2 million charge associated with certain states electing a 25% cash
conversion in lieu of product under the Nationwide Opioids Settlement Agreement,
partially offset by a $20.8 million discount recorded on the expected settlement
payments as of the agreement’s effective date, (ii) net charges associated with
antitrust class action litigation of $7.5 million, (iii) a charge related to
government investigations of $8.0 million, and (iv) immaterial net charges
related to several matters.
                                       15                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                               Specialty Segment                                
                                                                                
                                                                                
              Reconciliation of GAAP to Non-GAAP Operating Results              
                                                                                
                          (unaudited; $ in thousands)                           
                                                                                
           T…                                   T…                              
           M…                                   M…                              
           E…                                   E…                              
           S…                                   S…                              
           3…                                   3…                              
           2…                                   2…                              
 ────────────────────────────────────────────────────────────────────────────── 
       As           A…        N…           As            Ad…        No…         
       R…                                  Re…                                  
  …    $   1…       $    —    $   1…       $    1…       $     —    $    1…     
  …                                                                             
  …                                                                             
  …        4…           -…        2…            7…            -…         2…     
  …                                                                             
  …                                                                             
  …        1…           1…        1…            5…            4…         1…     
  …                                                                             
  …                                                                             
  …        6…  %                  8…  %         4…  %                    7…  %  
  %                                                                             
  …                                                                             
  …        3…           -…        3…            3…            -…         3…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        4…           -…        4…            8…            -…         6…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        55            —        55            59             —         59     
  …                                                                             
  …                                                                             
  …                                                                             
  …         —            —         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        35           -…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…            —        1…             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   6…       $   1…    $   8…       $    9…       $    5…    $    6…     
  …                                                                             
                                                                                
(1) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of amortization expense ($18.9 million and $26.5
million) and asset impairment charges (none and $22.1 million).

(2) Adjustments for the three months ended September 30, 2026 and 2025 were
comprised of stock-based compensation expense.

(3) Adjustments for the three months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($0.1 million
in each period) and site closure costs (none and $1.7 million).
                                       16                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                               Specialty Segment                                
                                                                                
                                                                                
              Reconciliation of GAAP to Non-GAAP Operating Results              
                                                                                
                          (unaudited; $ in thousands)                           
                                                                                
           N…                                   N…                              
           M…                                   M…                              
           E…                                   E…                              
           S…                                   S…                              
           3…                                   3…                              
           2…                                   2…                              
 ────────────────────────────────────────────────────────────────────────────── 
       As           A…        N…           As            Ad…        No…         
       R…                                  Re…                                  
  …    $   4…       $    —    $   4…       $    3…       $     —    $    3…     
  …                                                                             
  …                                                                             
  …        1…           -…        8…            1…            -…         6…     
  …                                                                             
  …                                                                             
  …        2…           5…        3…            1…            1…         2…     
  …                                                                             
  …                                                                             
  …        6…  %                  8…  %         4…  %                    8…  %  
  %                                                                             
  …                                                                             
  …        1…           -…        1…            9…            -…         9…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…           -…        1…            2…            -…         1…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…            —        1…            1…             —         1…     
  …                                                                             
  …                                                                             
  …                                                                             
  …        3…           -…         —            4…            -…          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        35           -…         —             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…            —        1…             —             —          —     
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   1…       $   5…    $   2…       $    6…       $    1…    $    1…     
  …                                                                             
                                                                                
(1) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of amortization expense ($56.4 million and $92.0
million) and asset impairment charges (none and $22.1 million).

(2) Adjustments for the nine months ended September 30, 2026 and 2025 were
comprised of stock-based compensation expense.

(3) Adjustments for the nine months ended September 30, 2026 and 2025,
respectively, were comprised of stock-based compensation expense ($0.4 million
and $0.3 million) and site closure costs (none and $3.1 million).
                                       17                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                                 AvKARE Segment                                 
                                                                                
                                                                                
              Reconciliation of GAAP to Non-GAAP Operating Results              
                                                                                
                                      (1)                                       
                                                                                
                          (unaudited; $ in thousands)                           
                                                                                
           T…                                  Th…                              
           M…                                  Mo…                              
           E…                                  En…                              
           S…                                  Se…                              
           3…                                  30,                              
           2…                                  20…                              
 ────────────────────────────────────────────────────────────────────────────── 
       As           A…        N…           As            A…         N…          
       R…                                  R…                                   
  …    $   1…       $    —    $   1…       $   19…       $     —    $   19…     
  …                                                                             
  …                                                                             
  …        1…            —        1…           15…             —        15…     
  …                                                                             
  …                                                                             
  …        3…            —        3…           42…             —        42…     
  …                                                                             
  …                                                                             
  …        2…  %                  2…  %        21…  %                   21…  %  
  %                                                                             
  …                                                                             
  …        1…           -…        1…           15…           -2…        12…     
  …                                                                             
  …                                                                             
  …    $   1…       $   2…    $   2…       $   27…       $   2,…    $   29…     
  …                                                                             
                                                                                
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal
products by AvKARE were included in our Affordable Medicines segment.

(2) Adjustments for the three months ended September 30, 2026 and 2025 were
comprised of amortization expense.
                                       18                                       
                                                                                
                          Amneal Pharmaceuticals, Inc.                          
                                                                                
                                                                                
                                 AvKARE Segment                                 
                                                                                
                                                                                
              Reconciliation of GAAP to Non-GAAP Operating Results              
                                                                                
                                      (1)                                       
                                                                                
                          (unaudited; $ in thousands)                           
                                                                                
           N…                                  Ni…                              
           M…                                  Mo…                              
           E…                                  En…                              
           S…                                  Se…                              
           3…                                  30,                              
           2…                                  20…                              
 ────────────────────────────────────────────────────────────────────────────── 
       As           A…        N…           As            A…         N…          
       R…                                  R…                                   
  …    $   4…       $    —    $   4…       $   53…       $     —    $   53…     
  …                                                                             
  …                                                                             
  …        3…            —        3…           42…             —        42…     
  …                                                                             
  …                                                                             
  …        1…            —        1…           10…             —        10…     
  …                                                                             
  …                                                                             
  …        2…  %                  2…  %        19…  %                   19…  %  
  %                                                                             
  …                                                                             
  …        5…           -…        4…           46…           -8…        37…     
  …                                                                             
  …                                                                             
  …    $   4…       $   7…    $   5…       $   58…       $   8,…    $   66…     
  …                                                                             
                                                                                
(1) Revenue, cost of goods sold, and gross profit from the sale of Amneal
products by AvKARE were included in our Affordable Medicines segment.

(2) Adjustments for the nine months ended September 30, 2026 and 2025 were
comprised of amortization expense.
                                       19                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AMRX/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.